Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
Jean-Claude Tardif,Marie-Pierre Dubé,Marc A. Pfeffer,David D. Waters,Wolfgang Koenig,Aldo P. Maggioni,John J.V. McMurray,Vincent Mooser,Harvey D. White,Therese Heinonen,Donald M. Black,Marie-Claude Guertin,dal-GenE Investigators +12 more
TLDR
The dal-GenE clinical outcome trial as discussed by the authors was designed to evaluate the effect of the cholesteryl ester transfer protein (CETP) modulator dalcetrapib on the composite of cardiovascular death, myocardial infarction or stroke.About:
This article is published in American Heart Journal.The article was published on 2020-01-17 and is currently open access. It has received 22 citations till now. The article focuses on the topics: Dalcetrapib & Cholesterylester transfer protein.read more
Citations
More filters
Journal ArticleDOI
A modern approach to dyslipidemia.
TL;DR: In this paper, an updated approach to diagnosis and risk assessment may include measurement of secondary lipid variables such as apolipoprotein B and Lipoprotein(a), together with selective use of genetic testing to diagnose rare monogenic dyslipidemias such as familial hypercholesterolemia or familial chylomicronemia syndrome.
Journal ArticleDOI
HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role.
TL;DR: For a long time, high-density lipoprotein cholesterol (HDL-C) has been regarded as a cardiovascular disease (CVD) protective factor as mentioned in this paper, which has further fueled the discussion on the pathophysiological role of HDL in CVD.
Journal ArticleDOI
High Density Lipoproteins and Diabetes
TL;DR: A recent review as discussed by the authors highlights focus areas that have yet to be investigated and potential strategies for exploiting the antidiabetic functions of HDLs, and highlights the potential strategies to exploit these functions.
Journal ArticleDOI
Physiological roles of mammalian transmembrane adenylyl cyclase isoforms
TL;DR: The transmembrane AC isoforms partition to different microdomains of the plasma membrane and form prearranged signaling complexes with specific GPCRs that contribute to cAMP signaling compartments as discussed by the authors .
Journal ArticleDOI
Physiological Roles of Mammalian Transmembrane Adenylyl Cyclase Isoforms.
Katrina F. Ostrom,Justin E. LaVigne,Tarsis F. Brust,Roland Seifert,Carmen W. Dessauer,Val J. Watts,Rennolds S. Ostrom +6 more
TL;DR: Adenylyl cyclases (ACs) catalyze the conversion of ATP to the ubiquitous second messenger cAMP as mentioned in this paper, and Mammals possess nine isoforms of transmembrane ACs, dubbed AC1-9, that serve as major effector enzyme.
References
More filters
Journal ArticleDOI
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine,Robert P. Giugliano,Anthony C Keech,Narimon Honarpour,Stephen D. Wiviott,Sabina A. Murphy,Sabina A. Murphy,Julia F Kuder,Julia F Kuder,Huei Wang,Thomas Liu,Scott M. Wasserman,Peter S. Sever,Terje R. Pedersen,Terje R. Pedersen +14 more
TL;DR: In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Journal ArticleDOI
Alirocumab and cardiovascular outcomes after acute coronary syndrome
TL;DR: Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than amongThose who received placebo.
Journal ArticleDOI
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz,Anders G. Olsson,Markus Abt,Christie M. Ballantyne,Philip J. Barter,Jochen Brumm,Bernard R. Chaitman,I. Holme,David Kallend,Lawrence A. Leiter,Eran Leitersdorf,John J.V. McMurray,Hardi Mundl,Stephen J. Nicholls,Prediman K. Shah,Jean-Claude Tardif,R. Scott Wright,R. Scott Wright +17 more
TL;DR: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Journal ArticleDOI
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Hps,Louise Bowman,Jemma C. Hopewell,Fang Chen,K Wallendszus,William M. Stevens,Rory Collins,Rory Collins,Stephen D. Wiviott,Stephen D. Wiviott,Christopher P. Cannon,Christopher P. Cannon,Eugene Braunwald,Emily L. Sammons,Martin J Landray +14 more
TL;DR: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use in the placebo group.
Journal ArticleDOI
Cardiovascular efficacy and safety of bococizumab in high-risk patients
Paul M. Ridker,James H. Revkin,Pierre Amarenco,Robert Brunell,Madelyn Curto,Fernando Civeira,Marcus Flather,Robert J. Glynn,Jean Gregoire,J. Wouter Jukema,Yuri Karpov,John J.P. Kastelein,Wolfgang Koenig,Alberto J. Lorenzatti,Pravin Manga,Urszula Masiukiewicz,Michael Miller,Arend Mosterd,Jan Murin,Jose C. Nicolau,Steven E. Nissen,Piotr Ponikowski,Raul D. Santos,Pamela F. Schwartz,Handrean Soran,Harvey D. White,R. Scott Wright,Michal Vrablík,Carla Yunis,Charles L. Shear,Jean-Claude Tardif +30 more
TL;DR: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococzumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower‐risk patients but did have a significant benefit in the Trial involving higher‐risk Patients.
Related Papers (5)
Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
Jean-Claude Tardif,Eric Rhéaume,Louis-Philippe Lemieux Perreault,Jean Grégoire,Yassamin Feroz Zada,Géraldine Asselin,Sylvie Provost,Amina Barhdadi,David Rhainds,Philippe L. L’Allier,Reda Ibrahim,Ruchi Upmanyu,Eric J. Niesor,Renée Benghozi,Gabriela Suchankova,Fouzia Laghrissi-Thode,Marie-Claude Guertin,Anders G. Olsson,Ian Mongrain,Gregory G. Schwartz,Marie-Pierre Dubé +20 more
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz,Anders G. Olsson,Markus Abt,Christie M. Ballantyne,Philip J. Barter,Jochen Brumm,Bernard R. Chaitman,I. Holme,David Kallend,Lawrence A. Leiter,Eran Leitersdorf,John J.V. McMurray,Hardi Mundl,Stephen J. Nicholls,Prediman K. Shah,Jean-Claude Tardif,R. Scott Wright,R. Scott Wright +17 more